CCIA
GBT

Campbell & Co Investment Adviser’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Campbell & Co Investment Adviser’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-7,921
Closed -$253K – 1003
2022
Q2 		$253K Sell
7,921
-5,005
-39% -$147K 0.07% 524
2022
Q1 		$448K Buy
+12,926
New +$386K 0.12% 316

Other funds holding GBT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Campbell & Co Investment Adviser's GBT Position: Q3 2022 in Review

Campbell & Co Investment Adviser sold out of Global Blood Therapeutics, Inc. (GBT) in Q3 2022, closing a stake of 7,921 shares — an estimated $253K sold.

Campbell & Co Investment Adviser first reported a position in GBT in Q1 2022 and held it in 2 quarters. The position peaked at $448K in Q1 2022. 247 funds tracked by Wall St. Rank hold GBT as of Q3 2022.

  • Campbell & Co Investment Adviser reported no remaining Global Blood Therapeutics, Inc. position as of Q3 2022 after selling out during the quarter.
  • Campbell & Co Investment Adviser sold 7,921 Global Blood Therapeutics, Inc. shares in Q3 2022, an estimated $253K.
  • Campbell & Co Investment Adviser first reported a position in Global Blood Therapeutics, Inc. in Q1 2022 and held it in 2 quarters.
  • Campbell & Co Investment Adviser's Global Blood Therapeutics, Inc. position peaked at $448K in Q1 2022.
  • 247 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q3 2022.

Based on Campbell & Co Investment Adviser's 13F filing for Q3 2022, filed 14 Nov 2022.